×

Tonghua Dongbao's Insulin Aspart, as part of basal-bolus therapy, approved for sale in China

Date：2021-10-21
Author：東寶
Views：3

Tonghua Dongbao's Insulin Aspart Injection (tradename: Ruisulin) was approved for sale in China the other day, adding another member to the Company's insulin analog family since the launch of Insulin Glargine in 2019. This basal-bolus insulin therapy will enrich the choices for patients with diabetes, and sharpen the Company's competitive edge and consolidate its lead in the field of diabetes treatment in China.

0 日韩精品区_久久精品99视频_精品综合一区二区三区_欧美久久综合 日韩精品区_久久精品99视频_精品综合一区二区三区_老司机精品久久 日韩精品区_久久精品99视频_精品综合一区二区三区_欧美综合久久

583--------m.yzziwei.cn

275--------m.fjldt.cn

61--------m.oiaw.cn

882--------m.mahuajiqi.cn

592--------m.sxdayang.com.cn

647--------m.mzjinxin.com.cn

1025--------m.uhx.net.cn

311--------m.bandan.com.cn

373--------m.jl5l5v.cn

490--------m.zggbc.cn